Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should KnowHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Johnson & Johnson (JNJ) Dips More Than Broader Markets: What You Should KnowZacks Equity ResearchZacksJanuary 3, 2020ReblogShareTweetShareJohnson & Johnson (JNJ) closed at $144.28 in the latest trading session, marking a -1.16% move from the prior day. This change lagged the S&P 500's 0.71% loss on the day. Meanwhile, the Dow lost 0.81%, and the Nasdaq, a tech-heavy index, lost 0.79%.Heading into today, shares of the world's biggest maker of health care products had gained 4.59% over the past month, outpacing the Medical sector's gain of 4.11% and lagging the S&P 500's gain of 4.77% in that time.Investors will be hoping for strength from JNJ as it approaches its next earnings release, which is expected to be January 22, 2020. On that day, JNJ is projected to report earnings of $1.86 per share, which would represent a year-over-year decline of 5.58%. Our most recent consensus estimate is calling for quarterly revenue of $20.78 billion, up 1.87% from the year-ago period.Investors might also notice recent changes to analyst estimates for JNJ. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.1% higher within the past month. JNJ is holding a Zacks Rank of #2 (Buy) right now.Digging into valuation, JNJ currently has a Forward P/E ratio of 16.08. This represents a premium compared to its industry's average Forward P/E of 15.54.We can also see that JNJ currently has a PEG ratio of 2.35. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.12 as of yesterday's close.The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 24, putting it in the top 10% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoHere are 5 reasons the stock market is having its worst decline since 2008, and only one of them is the coronavirusMarketWatchMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoTimeless Software (HKG:8028) Shareholders Have Enjoyed A 51% Share Price GainSimply Wall St.Stock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo FinanceMarket Recap: Friday, Dec. 13Yahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance